Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2004 Nov;5(11):681-9.

Part I: Vaccines for solid tumours.

Author information

  • 1Department of Oncological and Surgical Sciences, University of Padova, Italy. mocellins@hotmail.com <mocellins@hotmail.com>

Erratum in

  • Lancet Oncol. 2005 Jan;6(1):4.

Abstract

Active specific immunotherapy holds great potential in the search for new therapeutic approaches for patients with cancer. Much preclinical and clinical evidence has shown that the immune system can be polarised against malignant cells by several vaccination strategies. Although no anticancer vaccine can be recommended outside clinical trials at present, tumour response and immunological findings in animals and humans should prompt researchers to investigate further the potential of this biotherapy. We summarise strategies for cancer vaccines so far implemented in the clinical setting, report the results of more than 200 clinical trials published over the past two decades, and discuss insights into preclinical tumour immunology that might aid the design of the next generation of cancer vaccines.

PMID:
15522656
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk